Your institution may have access to this item. Find your institution then sign in to continue.
Title
Option agreement for license to develop and commercialize new HIV/AIDS therapeutic.
Abstract
Reports on Sequus Pharmaceuticals Inc.'s acquisition of an option to develop and commercialize Sheffield Medical Technologies Inc.'s Liposome-CD4 technology as an HIV therapeutic. Methods of inactivating HIV; Assurance of longer stay of the liposome complexes and its effectivity.